Key Metrics of Cytokinetics
Revenue$7.5M▼ 92.0% YoYFY 2023
Operating income−$496M▼ 53.1% YoY
Net profit−$526M▼ 35.3% YoY
Shareholders' equity−$386M
Market cap$8.7BCYTK · $62.33
Open jobs1
About Cytokinetics
Company details
- Website
- cytokinetics.com
- Founded
- 2004
- Listed
- Nasdaq: CYTK (since 2004)
Company summary
Legal nameCytokinetics Incorporated
TickerCYTK
ExchangeNasdaq
CountryUnited States
SEC CIK0001061983
Listed since2004
IndustryBiotechnology: Pharmaceutical Preparations
SectorOther Industries · Discovered Companies
Websitehttps://cytokinetics.com
US market & SEC filings
CYTK · Nasdaq · SEC CIK 0001061983
Last price · 24 Oct 2026
$62.33
−0.84%
Market cap$8.7B
P/E—On FY 2023 diluted EPS
Volume2,061,285
SectorHealth CareBiotechnology: Pharmaceutical Preparations
Country · IPOUnited StatesListed 2004
CYTK share price
Premium
Annual results (SEC EDGAR)
Revenue, operating income, net income, EPS, cash flow, assets, liabilities, equity and debt for every year filed with the SEC are part of the premium plan.
Sign in to continue See plans & pricingVendor checks & payment capacity
Sign in with access to company financials to review vendor evidence.
Registered office and contact
Registered officeSouth San Francisco
GSTIN—
Email—
Websitehttps://cytokinetics.com
Members / shareholders—
Directors and key people
Directors are read from the MGT-7 annual return and AOC-4 signatories.
Charges (secured borrowings)
0 registered charges. Lenders, amounts and dates are part of the premium plan.
Statutory auditors
Auditors are read from the AOC-4 auditor's report section.
Business activities and related parties
Principal business activities and related-party transactions are read from MGT-7 and AOC-4 filings.
Filings
No filings on record yet.